The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 23, 2020

Filed:

Jan. 13, 2017
Applicants:

University-industry Foundation, Yonsei University, Seoul, KR;

Jeuk Co., Ltd., Gyeongsangbuk-do, KR;

Inventors:

Kyoung-Je Cho, Gyeongsangbuk-do, KR;

Byoung Chul Cho, Seoul, KR;

Mi-Ran Yun, Gyeonggi-do, KR;

Kyoung-Ho Pyo, Seoul, KR;

Han Na Kang, Seoul, KR;

Hun-Mi Choi, Seoul, KR;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/40 (2006.01); A61K 31/4418 (2006.01); A61K 31/366 (2006.01); A61K 31/505 (2006.01); A61K 31/404 (2006.01); A61K 35/00 (2006.01); G01N 33/574 (2006.01); G01N 33/543 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4418 (2013.01); A61K 31/366 (2013.01); A61K 31/40 (2013.01); A61K 31/404 (2013.01); A61K 31/505 (2013.01); A61P 35/00 (2018.01); G01N 33/543 (2013.01); G01N 33/574 (2013.01); G01N 33/57423 (2013.01); G01N 2333/912 (2013.01);
Abstract

Provided are a pharmaceutical composition exhibiting therapeutic efficacy against EML4-ALK-positive non-small cell lung cancer that has acquired resistance to an ALK inhibitor and a method for treating the non-small cell lung cancer. Further, provided is information for drug selection for determining whether to administer a statin-based drug to a patient group with EML4-ALK-positive non-small cell lung cancer.


Find Patent Forward Citations

Loading…